How are energy investors positioned?
In a turbulent market environment, Zynex Inc. (NASDAQ:ZYXI) has seen its shares tumble to a 52-week low, touching down at $6.99. According to InvestingPro analysis, the company appears undervalued at current levels, with strong fundamentals including a robust gross profit margin of nearly 80%. The medical technology company, specializing in non-invasive pain management devices, has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of 43.65%. Investors have shown concern as the stock struggles to regain momentum amidst broader economic pressures and sector-specific challenges. The current price level marks a critical juncture for Zynex as it navigates through a phase of investor skepticism and market volatility. Despite these challenges, InvestingPro data reveals the company maintains a strong financial position with a current ratio of 3.94, indicating ample liquidity to meet short-term obligations. Get access to 10+ additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Zynex, Inc. has announced a partnership with Veterans Affairs Medical (TASE:BLWV) Centers across the United States to expand access to its noninvasive pain management devices. This collaboration is expected to significantly increase Zynex’s market presence within the VA’s extensive healthcare system, which serves over 9 million veterans annually. Currently, sales to the VA constitute less than 1% of Zynex’s total revenue, highlighting the potential for growth through this partnership. The VA healthcare network includes 171 medical centers and over 1,100 outpatient facilities, as well as approximately 700 Military Treatment Facilities operated by the Department of Defense. The company’s CEO, Thomas Sandgaard, emphasized Zynex’s commitment to enhancing care for veterans by providing non-opioid pain management solutions. The sales team at Zynex will work closely with healthcare providers within the VA and MTF networks to deliver its suite of treatments. While Zynex has expressed a positive outlook for this collaboration, it acknowledges uncertainties and risks in future business projections. The company has not disclosed the financial impact of the partnership or specific timelines for product rollout across the VA network.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.